Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals

Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.